EHRA score three (OR 18.7; 95 CI 3.82.1;PB1081|Accounting of Symptoms and Ejection Fraction Might Boost Prediction of Left Atrial Thrombus in Patients with Nonvalvular Atrial Fibrillation ahead of Catheter Ablation or Cardioversion I. Zaigraev; I. Yavelov; O. Drapkina; E. Bazaeva National Health-related Research Center for Therapy and Preventive Medicine of your Ministry of Health on the Russian Federation, Moscow, Russian Federation Background: Optimal method for prediction of left atrial thrombus (LAT) in BRD3 Inhibitor MedChemExpress sufferers with nonvalvular atrial fibrillation (NAF) isn’t established however. Aims: To evaluate possibilities for prediction of LAT just before catheter ablation or cardioversion in sufferers with NAF. Solutions: In a retrospective single-center study health-related records of 1994 individuals with NAF underwent transesophagealP 0.0001), left ventricular ejection fraction [EF] (OR 0.89; 95 CI 0.81.98; P = 0.017) and CHA 2DS2-VASc-RAF score (OR 1.24; 95 CI 1.04.50, P = 0.017) had been connected with LAT. Addition of EHRA score 3 (+11 points) and EF 48 (+6 points) to CHA2DS2-VAScRAF score enhanced C-statistics from 0.83 (95 CI 0.76.91) to 0.87 (95 CI 0.80.94). Optimal cut-off for modified CHA2DS2-VAScRAF score was eight points (OR 25.8; 95 CI five.912.three, P 0.0001). Sensitivity, specificity, positive and negative predictive values of CHA 2DS2-VASc-RAF and modified CHA 2DS2-VASc-RAF scores are presented inside the table 1 Conclusions: Accounting of severity of symptoms and reduced EF may possibly slightly boost predictive value of CHA 2DS2-VASc-RAF score for left atrial thrombus in patients with non-valvular AF prior to catheter ablation or cardioversion.TABLE 1 Predictive values of CHA2DS2-VASc-RAF and modified CHA2DS2-VASc-RAF scores for LAT in patients with NAF prior to catheter ablation or cardioversionHigh values of threat scores Sensitivity 90,6 93,five Specificity 57,1 , 64,0 PPV 30,2 34,9 NPV 96,7 97,9CHA 2DS2-VASc-RAF three pointsModified CHA 2DS2-VASc-RAF 8 pointsPPV constructive predictive value; NPV adverse predictive value.PB1082|Inappropriate Direct Oral Anticoagulant Dosing in a Spanish Cohort with Atrial Fibrillation B. Navarro Almenzar1; J.J. Cerezo Manchado2; F. Garc Candel1Methods: Retrospective study that included individuals with AF who started a DOAC (Rivaroxaban, Apixaban, Dabigatran or Edoxaban) from January 1, 2013 to December 31, 2016, in 3 Spanish hospitals (Hospital Cl ico Universitario Virgen de la Arrixaca, Hospital Comarcal del Noroeste and Hospital Vega Baja). Inappropriate dosing was analysed as outlined by labeling recommendations. Thromboembolic, hemorrhagic complications and mortality were recorded. Mean follow-up was 1,6 years. Statistical evaluation was performed applying SPSSStatistics plan v25 (SPSS Inc., Chicago, Illinois, USA). Outcomes: A total of 2218 patients were integrated, of which, 506 sufferers (23 ) had been receiving an inappropriate dose. Among these patients, inappropriate reduced dose (underdosing) predominated (87 ). Table 1 shows the main qualities of your cohort. Rivaroxaban was the drug incorrectly prescribed most often.Hospital Common Universitario Rafael M dez, Murcia, Spain; Hospital Basic Universitario Santa Luc , Murcia, Spain; HospitalCl ico Universitario Virgen de la Arrixaca, Murcia, Spain Background: Atrial fibrillation (AF) is definitely the most prevalent arrhythmia worldwide, being the main cause of anticoagulation. DOACS are made use of usually for the CYP2 Inhibitor list stroke prevention in these sufferers. Each and every DOAC has two presentations, the normal dos